Current Report Filing (8-k)
August 11 2016 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): August 9, 2016
NOVAVAX, INC.
(Exact name of registrant as specified
in charter)
|
|
|
|
|
Delaware
|
|
0-26770
|
|
22-2816046
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
20 Firstfield Road
Gaithersburg, Maryland 20878
(Address of Principal Executive Offices,
including Zip Code)
(240) 268-2000
(Registrant’s telephone number,
including area code)
(Former name or
former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
Second Quarter Financial Results
On August 9, 2016,
Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter
ended June 30, 2016. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information
in Items 2.02 and 9.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act except as expressly
set forth by specific reference in such a filing.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
Exhibit
No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press release, dated August 9, 2016, regarding the Company’s financial results for the quarter ended
June 30, 2016
.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
Novavax, Inc.
(Registrant)
|
|
|
|
|
Date: August 10, 2016
|
|
|
|
By:
|
|
/s/ John A. Herrmann III
|
|
|
|
|
|
|
Name:
|
|
John A. Herrmann III
|
|
|
|
|
|
|
Title:
|
|
Senior Vice President, General Counsel and
Corporate Secretary
|
|
|
|
|
|
|
|
|
|
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press release, dated August 9, 2016, regarding the Company’s financial results for the quarter ended
June 30, 2016
.
|
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024